Zhejiang Jianfeng Group(600668.SH): Application for the listing of Compound Tropicamide Eye Drops is not approved.

15:45 19/03/2026

Peak Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Peak Pharmaceutical Co., Ltd. (referred to as "Peak Pharma") received a "Notice of Disapproval of Drug Marketing Application" issued by the National Medical Products Administration for its compound tropicamide eye drops (0.5ml: tropicamide 2.5mg and epinephrine hydrochloride 2.5mg). The reason for the disapproval is as follows:

Zhejiang Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") received a "Notice of Disapproval of Drug Marketing Application" issued by the National Medical Products Administration for the compound tropicamide eye drops (0.5ml: tropicamide 2.5mg and hydrochloride norepinephrine 2.5mg). The reason is as follows: The provided research data cannot prove the rationality of the specifications of this product, which does not meet the requirements of the "Notice on the Issuance of 5 Drug Evaluation Technical Standards including Chemical Drug Technology Standards" (NMPA Announcement [2008] No. 271).

Stella Holdings (01836) will distribute a special dividend of HK$0.56 per share on June 5th.

LEGION CONSO (02129) issues profit warning, expecting a pre-tax loss of no less than SGD 5.1 million for the fiscal year 2025, compared to profit in the same period last year.

DYNAM JAPAN (06889) spent 1.6672 million Hong Kong dollars to repurchase 500,000 shares on March 19th.

Stella Holdings (01836) will distribute a special dividend of HK$0.56 per share on June 5th.

LEGION CONSO (02129) issues profit warning, expecting a pre-tax loss of no less than SGD 5.1 million for the fiscal year 2025, compared to profit in the same period last year.

DYNAM JAPAN (06889) spent 1.6672 million Hong Kong dollars to repurchase 500,000 shares on March 19th.